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ABSTRACT 
CAFFEINE MODEL IDENTIFICATION FOR VIGILANCE 
PERFORMANCE PREDICTION 
Chun-Hui Huang 
Old Dominion University 
Director: Dr. Jen-Kuang Huang 
The pharmacodynamics and pharmacokinetics of caffeine have been well 
characterized. In this study, a caffeine dynamic model is developed to describe its 
pharmacodynamic effects on vigilance performance. Validated biomathematical models 
developed to address both individual and group fatigue and alertness in a non-laboratory 
setting represent a tremendous commercial opportunity. First, a test data set with caffeine 
effects isolated from circadian and homeostatic effects is created. Then a modeling 
approach for input and output effects is developed and different model structures for the 
caffeine effects are considered. Observer/Kalman filter Identification (OKTD) algorithm 
is proposed and developed to identify the caffeine model from the created input/output 
data. The identified caffeine model is then tested to fit for the test data. In this caffeine 
model, five system parameters [alia2,cl,c2,d0'\ can be identified by using the proposed 
OKID algorithm. Identification of the individualized caffeine model shows that the first 
two coefficients [alfa2] have small variations for users of both low and high amounts of 
caffeine among all doses. The 100 mg model has a statistically higher caffeine response 
as compared to the response of the 200 mg or 300 mg models based on the individualized 
caffeine models identified from test data. The result also shows that users of both low and 
high amounts of caffeine users have comparable responses based on the 100 mg model. 
However, the responses of the 200 mg or 300 mg models show that users of high 
amounts of caffeine have a statistically higher response to caffeine. In conclusion, the 
results suggest that the caffeine dosage and habitual usage do not have much impact on 
the individualized caffeine model dynamics, and the proposed individualized caffeine 
model can be modified by adding a dose factor to the input of the model to improve the 
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Sleep deprivation and circadian misalignment occur frequently in military and labor 
operations, particularly during sustained operations and when multiple time zones are 
crossed during deployment. While sleep loss progresses, changes in performance and 
alertness occur in response to both increasing homeostatic sleep drive and circadian 
variation, resulting in an accumulation of performance deficits over time, superimposed 
on circadian modulation. Caffeine is a commonly used stimulant, known to alleviate the 
effects of sleep deprivation and fatigue. The pharmacodynamics and pharmacokinetics of 
caffeine have been well characterized. It is rapidly absorbed after oral dosing, and 
extensively metabolized. In military operations involving round-the-clock missions and 
travel across multiple time zones, biomathematical caffeine models of human 
performance have potential as tools for predicting, analyzing, and estimating the dose 
effect and habitual effect on the fatigue and performance of sleep-deprived soldiers. 
Validated biomathematical models developed to address both individual and group 
fatigue, sleepiness, and performance in non-laboratory settings represent a tremendous 
commercial opportunity. There is an articulated need to quantify the risks associated with 
worker fatigue, optimize schedules and procedures, and apply appropriate fatigue 
countermeasures to ensure acceptable levels of operational performance and safety. 
* Methods in Enzimology of Academic Press was used as format model for this dissertation 
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Applications based on the tools in this research can help meet these needs, particularly in 
areas where human performance has important safety implications, such as military 
operations, air travel, emergency health care, shift work, etc. Therefore, it is essential to 
design biomathematical model development and system identification techniques, and 
develop a comprehensive set of caffeine model structures from both group and individual 
data sets. This approach allows a broad range of possible models to be analyzed and 
predicted. The data sets are from the U.S. Department of Defense, involving subjects 
repeating for one night total sleep deprivation conditions with caffeine doses 
administered through the night. 
1.2 Objective 
The objective of this research is to develop pharmacodynamic and forecasting 
models of caffeine administration as fatigue and performance countermeasures using a 
dynamic, individualized modeling framework. Models are developed that combine 
parameters such as dosage and administration timing with caffeine-related individual 
traits and habituation factors related to recent daily caffeine consumption. The research 
focuses on caffeine consumed in gum form. This modeling approach therefore starts with 
a comparative assessment of a range of model structures of various orders. Following 
testing, the most effective and parsimonious of the models is selected for subsequent 
integration with the Observer / Kalman Filter Identification (OKID) model. It is shown 
that the proposed individualized caffeine model can be modified by adding a dose factor 
to the input of the model to improve the prediction for the performance of other caffeine 
doses. 
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1.3 Dissertation Outlines 
In this study, a caffeine dynamic model is developed to describe its 
pharmacodynamics effects on vigilance performance. First, a test data set with caffeine 
effects isolated from circadian and homeostatic effects is created. Then a modeling 
approach for input and output effects is developed and different model structures for the 
caffeine effects are considered. A system identification algorithm called 
Observer/Kalman filter Identification (OKID) is proposed and developed to identify the 
caffeine model from the created input/output data. The identified caffeine model is then 
tested to fit for the test data. 
From the identified caffeine models, the effect of input noise and the model order on 
the modeling error is evaluated and an optimal model order is selected. After considering 
several model structures, an optimal caffeine model is recommended. Suitable caffeine 
parameters for individualization are identified. Based on the individualized models 
identified, the predicted caffeine performance for different caffeine dose and habitual 
caffeine usage is investigated. Finally, from the study of the group average and 
individualized caffeine-only test data, a state-space caffeine model in controllable 
canonical form is proposed for future study to merge into a two-process model with 




2.1 Caffeine Effects 
It is well known that caffeine has effects on human behavior such as alertness, mood, 
mental performance and sleep. The effects of low doses (75 mg and 150 mg) of caffeine 
on mood and cognition in healthy people were evaluated, with minimal abstinence from 
caffeine of 1 hour. Improvements were obtained in cognition for attention, problem 
solving and delayed recall, but not immediate recall or working memory, but 
performance in the placebo condition was close to the maximum, giving little margin for 
improvement. For mood, there were statistically significant increases in clear-headedness, 
happiness and calmness and decreases in tenseness. These mood and performance-
enhancing effects of caffeine cannot be seen as representing an alleviation of deficits 
induced by caffeine abstinence, because there was only minimal deprivation from 
caffeine (Warburton, 1995). In addition, the effects of caffeine on sleep inertia, which is 
the ubiquitous phenomenon of cognitive performance impairment, are that grogginess 
and tendency to return to sleep immediately after awakening. Caffeine was efficacious in 
overcoming sleep inertia. Caffeine's main mechanism of action on the central nervous 
system is antagonism of the adenosine receptor. Thus, increased adenosine in the brain 
upon awakening may be the cause of sleep inertia (Van Dongen et al., 2001). The ability 
of high doses of caffeine is assessed to reverse changes in alertness and mood produced 
by prolonged sleep deprivation (Penetar et al., 1993). In fact, there is little evidence 
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concerning the effects of caffeine in doses typical of one cup of tea. Durlach's study 
investigated the effect of 60 mg caffeine, consumed in either tea or hot water, on 
performance. The four beverages were created by crossing beverage identity (tea or hot 
water) and caffeine dose (0 or 60 mg). Significant speeding of reaction time by caffeine 
consumption was found in pattern recognition, delayed match to sample, and match to 
sample visual search. The effect on reaction time of 60 mg caffeine can be detected, and 
may be evident within minutes of consumption. Despite objective reports of immediate 
beneficial effects of consumption, most research has postponed measurement to coincide 
with peak plasma caffeine levels. The study was to investigate the effects of consuming a 
single cup of tea on a variety of cognitive tests (Durlach, 1998). A review of Lieberman's 
studies examined whether moderate doses of caffeine would reduce the adverse effects of 
sleep deprivation and exposure to severe environmental and operational stress on 
cognitive performance. Even in the most adverse circumstances, moderate doses of 
caffeine can improve cognitive function, including vigilance, learning, memory, and 
mood state. When cognitive performance is critical and must be maintained during 
exposure to severe stress, administration of caffeine may provide a significant advantage 
(Lieberman and Tharion, 2002). Smith's study suggests that the following effects on 
behavior of adult humans may occur when individuals consume moderate amounts of 
caffeine (Smith, 2002). Caffeine increases alertness and reduces fatigue. This may be 
especially important in low arousal situations (e.g. working at night). Caffeine improves 
performance on vigilance tasks and simple tasks that require sustained response. Again, 
these effects are often clearest when alertness is reduced, although there is evidence that 
benefits may still occur when the person is unimpaired. Effects on more complex tasks 
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are difficult to assess and probably involve interactions between the caffeine and other 
variables that increase alertness (e.g. personality and time of day). In contrast to the 
effects of caffeine consumption, withdrawal of caffeine has few effects on performance. 
There is often an increase in negative mood following withdrawal of caffeine, but such 
effects may largely reflect the expectancies of the volunteers and the failure to conduct 
"blind" studies. Regular caffeine usage appears to be beneficial, with higher users having 
better mental functioning. McLellan's study has demonstrated the effectiveness of 
caffeine for maintaining the performance of military tasks during a period of sleep 
deprivation. Vigilance during both a live-fire marksmanship task and in an urban 
operations environment was maintained at control levels when caffeine was ingested 
throughout the evening. The findings support the recommendation that during periods of 
unavoidable sleep loss the use of caffeine can extend the period of operational 
effectiveness during the conduct of military operations (McLellan et al., 2005). 
Most people are very good at controlling their caffeine consumption to maximize the 
above positive effects. For example, the pattern of consumption over the day shows that 
caffeine is often consumed to increase alertness. Indeed, many people do not consume 
much caffeine later in the day since it is important not to be alert when one goes to sleep. 
In contrast to effects found from normal caffeine intake, there are reports that have 
demonstrated negative effects when very large amounts are given or when sensitive 
groups (e.g. patients with anxiety disorders) were studied. In this context caffeine has 
been shown to increase anxiety and impair sleep. There is also some evidence that fine 
motor control may be impaired as a function of the increase in anxiety. Overall, the 
global picture that emerges depends on whether one focuses on effects that are likely to 
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be present when caffeine is consumed in moderation by the majority of the population or 
on the effects found in extreme conditions. The evidence clearly shows that levels of 
caffeine consumed by most people have largely positive effects on behavior. Excessive 
consumption can lead to problems, especially in sensitive individuals. 
The optimal dose of caffeine for sustaining performance has been determined during 
sleep loss with administration of multiple doses (Kamimori et al., 2005). When used to 
counteract the effects of sleep deprivation, multiple doses of caffeine are typically 
ingested across an extended period of time. The rapid delivery of caffeine in a chewing 
gum formulation can successfully maintain vigilance on a simple reaction time task using 
a multiple administration paradigm during a night without sleep. The ability of caffeine to 
improve or maintain alertness is directly dependent on the amount ingested, an 
individual's sensitivity to caffeine and on how fast it is ingested and absorbed into the 
body. The study findings demonstrate the efficacy of a multiple caffeine administration 
paradigm for maintenance of vigilance during simple reaction time performance through 
a night without sleep. Although any dose of caffeine was significantly better at 
countering the performance decrements observed in the placebo group, the 200-mg dose 
was most effective. 
2.2 Pharmacokinetics and Psychomotor Effects of Caffeine 
Both the pharmacokinetics and psychomotor effects of caffeine in humans have been 
investigated. Most research focused on the pharmacokinetics effect by finding the 
plasma caffeine level from the blood samples after the caffeine is administered. Robelin's 
study suggests that there is little net benefit to be gained from frequent caffeine use. At 
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the very least, it appears that the psychostimulant effects of caffeine cannot on their own 
account for the typical pattern of consumption of caffeine-containing drinks (Robelin and 
Rogers, 1998). Bovim's investigation was of the possible influence of caffeine upon 
motor steadiness performance in tests routinely used in neuropsychological testing. A 
significantly poorer motor steadiness performance was found after ingestion of 300 mg of 
caffeine as compared to a placebo (decaffeinated coffee). Both error time and error count 
were increased after caffeine consumption. Caffeine also tended to reduce maze 
coordination test performance. Hence, caffeine intake preferably should be avoided 
before neuropsychological testing of motor steadiness (Bovim et al, 1995). Furthermore, 
high-frequency low-dose caffeine administration is effective in countering the 
detrimental performance effects of extended wakefulness (Wyatt et al., 2004). 
Kaminmori studied body absorption of a single caffeine dose ingested in capsule form 
and as a gum to evaluate the rate and extent of absorption of three doses of caffeine from 
a gum versus a capsule formulation (Kamimori et al., 2002). The results indicate that the 
rate of drug absorption is significantly faster for the gum formulation. Although the 
bioavailabilities for 50, 100 and 200 mg gum groups are reported as 64, 74 and 77%, 
these bioavailabilities were based on 100% release of caffeine from the gum. However, 
data indicate that only 85% of the caffeine is released from the gum following 5 min of 
chewing (Novum, 2000). Based on an 85% dose, the mean bioavailabilities may be 75, 
87 and 90% for the 50, 100 and 200 mg groups, respectively. It appears that for the 100 
and 200 mg groups, the gum and capsule formulations provide a near comparable amount 
of caffeine to the systemic circulation. These findings suggest that both physical and 
mental performance deficits resulting from sleep loss or fatigue could be more quickly 
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reversed by caffeine administered in a chewing gum formulation compared with a 
capsule formulation. 
Although the caffeine delivered through the gum formulation was intended to be 
absorbed through the oral mucosa, the use of four sticks of gum may have resulted in 
increased salivation (due to the large size of the gum cud) and a corresponding increase 
in the portion of the drug being swallowed with the saliva. The portion of caffeine 
swallowed in the saliva would be absorbed in the gastrointestinal tract, just like a capsule. 
In fact, we did observe multiple peaks in the plasma profiles of a number of subjects 
corresponding to multiple sites of absorption. Dual absorption sites could result in an 
immediate increase in plasma caffeine levels via absorption through the oral mucosa, 
followed by another peak corresponding to subsequent absorption in the gastrointestinal 
tract. However, this may have contributed to the high variability of the pharmacokinetic 
parameters, indicated by their high standard deviations. High variability could have also 
resulted from a parallel design of the study. Although a cross over study would have been 
the most elegant design, it was technically difficult. If the study was performed with a 
cross over design, there was an element of learning in the pharmacodynamic tasks that 
the subjects were asked to perform. Additionally, the subjects would alter their sleep 
pattern before their second study date based on their experience with the first study date. 
This would introduce bias and errors in the pharmacodynamic measurements. Caffeine 
improves performance and alertness in sleep deprived subjects, and in individuals who 
are required to work through the nadir of the circadian rhythm of alertness and 
performance in the early morning hours (e.g. medical and emergency personnel, long 
haul truckers, and shift workers) (Akerstedt and Ficca, 1997; Reyner and Home, 1998). 
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Furthermore, the act of chewing gum itself has been shown to increase alertness in night 
shift workers (Hodoba, 1999). 
Syed investigated body absorption of multiple caffeine doses ingested in gum (Syed 
et al., 2005). The rate of drug absorption from the gum formulation was significantly 
faster and may indicate absorption via the buccal mucosa. In addition, for the 100 and 
200 mg groups, the gum and capsule formulations provide near comparable amounts of 
caffeine to the systemic circulation. These findings suggest that there may be an earlier 
onset of pharmacological effects of caffeine delivered in the gum formulation, which is 
advantageous in situations where the rapid reversal of alertness and performance deficits 
resulting from sleep loss is desirable. Their experimental results showed that the caffeine 
concentration can be described by a first order differential equation. A higher 
concentration of caffeine was found with higher intake dose level and had a nonlinear 
relationship with intake dose level. 
Kaplan et al., 1997 also found that caffeine kinetics was nonlinear and the high-dose 
caffeine (250-500mg) produced less performance enhancement than the lower dose. 
Twelve healthy volunteers received an oral placebo, 250 mg of caffeine, and 500 mg of 
caffeine in a randomized, double-blind, single-dose crossover study. Caffeine kinetics 
was nonlinear, with clearance significantly reduced and elimination half-life prolonged at 
the 500 mg compared to the 250 mg dose. The lower dose of caffeine produced more 
favorable subjective effects than the higher dose (elation, peacefulness, pleasantness), 
whereas unpleasant effects (tension, nervousness, anxiety, excitement, irritability, nausea, 
palpitations, restlessness) following the 500 mg dose exceeded those experiments of the 
250 mg dose. The lower dose of caffeine enhanced performance during the digit symbol 
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substitution test and the tapping speed test when compared to tests run with the placebo. 
High-dose caffeine produced less performance enhancement than the lower dose. The 
plasma concentration versus response relationship revealed concentration-dependent 
increases in anxiety and improvements in cognitive and motor performance at low to 
intermediate concentrations. 
Both caffeine doses reduced electroencephalographic amplitude over the 4 Hz to 30 
Hz spectrum, as well as in the alpha (8-11 Hz) and beta (12-30 Hz) ranges; however, 
effects were not dose-dependent. While favorable subjective and performance-enhancing 
stimulant effects occur at low to intermediate caffeine doses, the unfavorable subjective 
and somatic effects, as well as performance disruption, from high doses of caffeine may 
intrinsically limit the doses of caffeine used in the general population. 
Among the literatures surveyed, no suitable caffeine model has been found to represent 
the pharmacodynamics effects of caffeine on humans. 
2.3 Techniques of Modeling 
The process of using observed data to a mathematical model is fundamental in 
science and engineering. In the control area this process has been termed "System 
Identification" and the objective is then to find dynamical models (difference or 
differential equations) from observed input and output signals. Its basic features are, 
however, common with general model building processes in statistics and other sciences. 
System Identification has been an active research area for more than thirty years. It 
has matured and many of the techniques have become standard tools in control and signal 
processing engineering. The approach is described Ljung (Ljung, 1987) and Soderstrom 
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(Soderstrom and Stoica, 1989). Over the past decades, there has been a significantly 
renewed interest in the area with topics like "unknown-but-bounded" disturbances 
(Schweppe, 1968) and (Milanese and Belforte, 1982), set membership techniques (Fogel, 
1979; Norton, 1987) subspace techniques (Van, 1994), Hx identification (Parker and 
Bitmead, 1987; Helmicki, 1991), worst case analysis Guo and Khargonekar, 1992; 
Makila and Partington, 1991), as well as how to deal with unopened dynamics (Ninness, 
1993). Ljung gave an overview and discussion of the basic steps of system identification 
(Ljung, 1994). The four main ingredients of the process that take us from observed data 
to a validated model are: (1) the data itself, (2) the set of candidate models, (3) the 
criterion of fit and (4) the validation procedure. 
System Identification is used to develop an appropriate model of a dynamic system 
using observed data combined with prior knowledge of relationships between signals, 
input and output. It allows us to establish models for systems with very complex 
dynamics and/or systems with unknown physical parameter values. Juang built a bridge 
between the disciplines of system identification as applied to controls and to modal 
testing (Juang, 1994). The solid theoretical and methodological foundations from the 
control area should be combined with the extensive experimental knowledge from the 
modal testing field. When performing system identification experiments, we need to have 
the purpose of the identification in mind. In control problems, the final goal is to design 
control strategies for a particular system. The major benefit of system identification is the 
improvement of the analytical model of a system. System Identification is widely applied 
in many fields now, including ambient vibration testing and structural evaluation of an 
historic suspension footbridge (Gentile and Gallino, 2008), how stochastic sampling jitter 
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noise affects the result of system identification (Eng and Gustafsson, 2008), guided basis 
selection for reduced-order nonlinear response analysis (Rizzi and Przekop, 2008), the 
energy performance assessment of buildings and building components (Androutsopoulos 
et al., 2008), dynamic fuel cell stack model for real-time simulation (Meiler et al., 2008), 
modeling plant control strategies and their applications into a knowledge-based system 
(Marumo and Sebusang, 2008), input-output modeling with decomposed neuro-fuzzy 
ARX model (Golob and Tovornik, 2008), fast robust regression algorithms for problems 
with Toeplitz structure (Mastronardi and O'Leary, 2007), nonlinear system 
identification and control of chemical processes using fast orthogonal search (Eklund et 
al., 2007), FPGA implementation of a systems identification module based upon 
Hopfield networks (Atencia et al., 2007), A genetic approach to modeling fuzzy systems 
based on information granulation and successive generation-based evolution method 
(Park, 2007), dynamic characteristics of a curved cable-stayed bridge identified from 
strong motion records (Siringoringo and Fujino, 2007), isometric muscle contraction 
induced by repetitive peripheral magnetic stimulation (RPMS)—modeling and 
identification (Bernhardt et al., 2007) and system identification of photosensitiser uptake 
kinetics in photodynamic therapy (Bastogne et al., 2007). 
A system identification algorithm called Observer/Kalman filter Identification 
(OKID) is proposed and developed to identify the caffeine model from the created 
input/output data. The Markov parameters can then be used for identification of a state 
space representation, with associated Kalman gain or observer gain, for the purpose of 
controller design. The algorithm is a non-recursive matrix version of two recursive 
algorithms developed in previous works for different purposes, and the relationship 
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between these other algorithms is developed. The new matrix formulation here gives 
insight into the existence and uniqueness of solutions of certain equations, and gives 
bounds on the proper choice of observer order. It is shown that if one uses data 
containing noise, and seeks the fastest possible deterministic observer, the deadbeat 
observer, one instead obtains the Kalman filter. It is important that the mathematical 
models obtained by means of system identification methods can be directly used for 
control system design purposes. This implies that linear models that take into account 
couplings between different motions should be determined. In fact, in such cases, linear 
control algorithms can be easily implemented and the effect of neglected dynamics can 
be minimized. An identification method that is potentially capable of coping with these 
requirements is observer/Kalman filter identification (OKID) that has proven to be 
numerically very efficient and robust with respect to measurement noise and even in the 
presence of mild nonlinearities. A number of successful applications of this method in the 
area of structural mechanics and aerospace engineering have been developed in recent 
years. The identified caffeine model is then tested to fit for the test data. Currently, 
observer/Kalman filter identification (OKID) algorithm applied to the identification of 
linear discrete-time multivariable models of an autonomous underwater vehicle (AUV) 
(Tiano et al., 2007), active vibration control of piezoelectric smart structures (Dong et al., 
2006), low-order tuner for fault-tolerant control of a class of unknown nonlinear 
stochastic sampled-data systems (Chein et al. 2007), and to identify dynamic models of 
mechanical structures for comparison study of subspace to flexible structures 
(Abdelghani et al., 1998). 
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CHAPTER 3 
PREPARATION OF INPUT/OUTPUT DATA FOR CAFFEINE 
MODELING 
Our caffeine modeling begins with a black-box system identification approach as 
no suitable pharmacodynamics caffeine model has been found in the literature. Several 
laboratory-based test data sets have been provided by the Walter Reed Army Institute of 
Research for study. They include Gum 2 data sets with 0, 50, 100 and 200 mg caffeine 
doses and Gum 3 data sets with 0, 100, 200 and 300 mg caffeine doses for repeated high 
and low users of caffeine. It involved a total sleep deprivation condition with three 
caffeine boluses administered at 0, 120 and 240 minutes. All the data measured are for 
1,000 ms lapses during a 10 minute PVT (Syed et al., 2005). 
A test data set is created with the population averages for four conditions (see 
Figure 3.1) for Gum 2 data (0, 50, 100 and 200 mg), four conditions (see Figure 3.3) for 
Gum 3 low-user data (0, 100 and 200 and 300 mg), and four conditions (see Figure 3.5) 
for Gum 3 high-user data (0, 100, 200 and 300 mg). The measurements are conditioned 
for use as the output test data for system identification by subtracting each performance 
data for the caffeine case from the placebo data (0 mg). The created output data for the 
Gum 2 study is shown in Figure 3.2, for the Gum 3 low-user study in Figure 3.4, and for 
the Gum 3 high-user study in Figure 3.6. It is noted that a higher value of lapses shown 
in this caffeine-only data indicates higher alertness. 
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The caffeine input is structured as impulses proportional to the caffeine dose with 
additive white process noise. The impulse level selected is 5, 10, 20 and 30 for 50, 100, 
200 and 300 mg caffeine doses, respectively. Figure 3.7 shows the input signal used for 
system identification for the Gum 3 200 mg high-user caffeine dose cases. 
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 400 510 540 
Running Time (min) 
Figure 3.1: Population average performance measurements from the four test 
groups in the Gum 2 user data set. 
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Figure 3.2: Differential effects between the Gum 2 user performance data and 
placebo data using population averages. 
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Figure 3.3: Population average performance measurements from the four test 
groups in the Gum 3 low-user data set. 
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Figure 3.4: Differential effects between the Gum 3 low-user performance data 
and placebo data using population averages. 
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Figure 3.5: Population average performance measurements from the four test 
groups in the Gum 3 high-user data set. 
19 
Gum 3 High Data 
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Figure 3.6: Differential effects between the Gum 3 high-user performance data 
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Figure 3.7: Input model showing caffeine impulse inputs for Gum 3 200 mg 
high-user at times 0, 120 and 240 min. with additive white process noise. 
CHAPTER 4 
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SYSTEM IDENTIFICATION METHOD 
4.1 Observer/Kalman Filter Identification (OKID) Algorithm 
In the past decades, many system identification techniques have been developed 
and/or applied to identify a system model from test data. The Observer/Kalman filter 
identification (OKID) algorithm was first derived by Phan and then applied to many 
applications (Phan et al., 1992; Juang, 1994). The derivation of this algorithm is 
presented in this section. 
A linear system can be represented by 
X(£ + 1) = AX(£) + Bu(£) 
y(k) = CX(*) + Du(*) ' 
where X(k) ei?", j(k) e Rm,u(k) eRr are state, output and control input with dimension 
of n,m,r respectively. From Eq. (4.1), the outputs y(k) with zero initial state can be 
written in terms of the inputs u(/), (i = 0,1,2, • • •, k) as 
y(0) = Du(0) 
y(l)=CX(l) + Du(l) 
= CAX(O) + CBu(O) + Du(l) 
y(2) = CX(2) + Du(2) 
= C[AX(1) + Bu(l)] + Du(2) 
= CA2X(0) + CBu(O) + CBu(l) + Du(2) 
y(3) = CX(3) + Du(3) 
= C[AX(2) + Bu(2)] + Du(3) 
= CA[AX(1) + Bu(l)] + CBu(2) + Du(3) 
= CA2X(1) + CABu(l) + CBu(2) + Du(3) 
= CA2 [ AX(O) + Bu(O)] + CABu(l) + CBu(2) + Du(3) 
- CA3X(0) + CA2Bu(0) + CABu(l) + CBu(2) + Du(3) 
k-\ 
y(k) = CA*X(0) + £CA*-wBu(/) + Du(&) 
(=0 
(4 
When the initial state is zero, it can be written in the matrix form 
rax/ rlxl 




y = [ y W Y(\) i(2) - y(i-\)] 
Y = [D CB CAB C A / 2 B ] 
U = 
u ( 0 ) u ( l ) u ( 2 ) 
u ( 0 ) u ( l ) 
u ( 0 ) 
u ( / - 1) 
u (/ - 2 ) 
u ( / - 3) 
u ( 0 ) 
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The matrices D,CB,CAB,--,CA*_1B are called system Markov Parameters, and 
are commonly used as the basis to identify mathematical models for linear dynamic 
systems. A linear state-space model can be derived by forming a Hankel matrix using 
system Markov parameters. 
For lightly damped systems, however, the slow decaying response may produce a 
large Hankel matrix, and long computation time. The OKID method solves this problem 
by adding an observer the system and placing desired eigenvalues, thus "forcing" the 
observer Markov parameters to be deadbeat. It adds and subtracts a term Gy(k) to the 
right-hand side of the state equation in Eq. (4.1), which yields 
x(k +1) = Ax(k) + Bu(k) + Gy(&) - Gy(k) 
- (A + GC)x(yt) + (B + GD)u(yt) - Gy(k) 
or x(k +1) = Ax(yt) + Bv(k) (4.4) 
where 
A = A + GC, B = [B + GD - G ] , v(k) = 
and G is an n x m arbitrary matrix chosen to make the matrix A as stable as desired, i.e. 





From Eq. (4.4), the output y(k) with nonzero initial state can be written in terms of the 
inputs v(z') (/ = 0,1,2, • • •, k) as 
y(0) = CX(0) + Du(0) 
y(l) = CX(l) + Du(l) 
= CAX(O) + CBv(O) + Du(l) 
y(2) = CX(2) + Du(2) 
= C[AX(1) + Bv(l)] + Du(2) 
= CA2X(0) + CBv(O) + CBv(l) + Du(2) 
y(3) = CX(3) + Dv(3) 
= C[ AX(2) + Bv(2)] + Du(3) 
= CA[ AX(1) + Bv(l)] + CBv(2) + Du(3) 
= CA2X(1) + CABv(l) + CBv(2) + Du(3) 
= CA2 [ AX(0) + Bv(0)] + CABv(l) + CBv(2) + Du(3) 
= CA3X(0) + CA2Bv(0) + CABv(l) + CBv(2) + Du(3) 
y(*) = CA*X(0) + £cA*-1_, 'Bv(0 + Du(ife) 
1=0 
It can be written in the matrix form 
y=init + YV (4.5) 
where 
y = [y(p) y(p+V - y ( / - i ) ] 
Y - [ D CB CAB CA*"1;1] 
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V = 
' n(p) u(p + l) - u ( / - l ) 
v(p-l) v(p) ••• v ( / -2) 
vQ>-2) v(/>-l) - v( / -3) 
v(0) v(l) - v( /- />-l)_ 
ZTKY = [CA'XCO) CA*+1X(0) ••• CA'-'-'XCO)] 
The matrices D,CB,CAB,---,CArp"i;B are called observer Markov parameters. 
The first term in Eq. (4.5) represents the effect of the preceding p-1 time steps. When 
Ap is sufficiently small and all the states in x are bounded, Eq. (4.5) can be 





From Eq. (4.6), we can calculate the observer Markov parameters from the 
input/output data. The system Markov parameters can then be recovered from the 
observer Markov parameters Y through partition of Y as: 
Y=[D CB CAB CA(p-1>B]=[Y0 Yj Y YJ 
where the observer Markov parameters are 
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Y0=D 
Y t = C A ^ B 
=[C(A + GCf (B + GD) - C(A + GC)* J G] 
= [Yf -Yf]; £ = 1,2,3,-
(4.7) 
The system Markov parameters can be calculated from the observer Markov parameters 
as 
Y, = CB=C(B + GD) - (CG)D 
= Y (V vf2J Y/z;D 
Y2 =CAB (4.8) 
= Y 2 '
U -Y 1^Y 1 -Y 2^D (Vt 
According to the above derivation, the general relationship between the system Markov 
parameters and the observer Markov parameters is 
D=Y0=Y0 
Y t = Y ,
( 1 ) - £ Y / 2 % _ 0 fovk = l,-,p 
Y t = - ^ Y /
2 ) Y ( i W ) fovk = p + l,p + 2-
(=i 
(4.9) 
or it can be written in system of equation as 
r(2) 
F(2) v ( 2 ) 
V<2> V ( 2 ) V ( 2 ) lp-\ X p - 2 lp-3 
r(l) V(2) 





( 1 )-YfD 
Y(1)- •YfD 
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Finally, the desired discrete system realization [A,B,C,D] can obtained from the system 
Markov parameters from singular value decomposition (SVD) of the Hankel matrix in 
Eq. (4.5) (see Figure 4.1 to 4.3). 
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Figure 4.2: Singular values from Gum 3 low-user using population averages. 
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Figure 4.3: Singular values from Gum 3 high-user using population averages. 
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H(*-l) = 
Y Y ••• Y 
-1* x *+l xjt+ /3-l 
Y Y ••• Y 
1 k+\ x k+2 x k+fi 
Y Y ••• Y 
*-k+a-l xk+a ^k+a+p-l 
(4.10) 
H(0)=R„ESn 
1 /2T»7 'TT/1 \C< V - 1 / 2 A=CR;H(1)S ,S ; 
C=ElRE Tn y , l /2 
D = Yn 
where E^ =[lm O m - O j , E^ =[lr O r -O r ] 
The estimation system can be represented by 
(4.11) 
X(* + l) = AX(Jt) + Bu(ifc) 
y(k) = CX(k) + i>u(k) 
(4.12) 
The caffeine model can be identified by using the OKID algorithm with the following 
steps: 
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a. Obtain input/output time histories data. 
b. Calculate Observer Markov parameters. 
c. Calculate System Markov parameters. 
d. Choose system order after finding singular values of the system Hankel matrix. 
e. Find system matrices A, B, C, D. 
f. Derive system parameters. 
Observer/Kalman Filter Identification (OKID) 
I/O Test 
Data* 
Observer % * i « m 
+ Markov > M«rjbav 
X o d e l 
{A, B , C D ] 
Singular Valae HlMMKflSl 
Matrix 
Figure 4.4: Procedure for Observer/Kalman filter identification (OKID) algorithm 
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4.2 Model Validation 
The multi-pulse input signal without additive white process noise is used as the input 
to the identified model for output estimation. The accuracy of the identified model is 





Ye,2 , ei - estimated value - test data at time step i (4.13) 
\ n /=i J 
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CHAPTER 5 
CAFFEINE MODEL USING POPULATION AVERAGE DATA 
The OKID algorithm is used to identify the caffeine model for the Gum 2 and Gum 3 
population average data. In each case, several sets of white process noise are added to 
the multi-pulse input. From OKID, a second order caffeine model is identified for each 
set of input noise. After model validation, the model with the least modeling error is 
selected as the identified model. From the identified caffeine model, the effect of input 
noise and model order on the modeling error is evaluated and an optimal model order is 
selected. After considering several model structures, an optimal caffeine model is 
recommended. 
5.1 Identified Caffeine Model Using Population Average Data 
As a demonstration, this approach applied to the Gum 3 200 mg high-user case 
yields a caffeine effects model of 






, B = 
"- 0.960" 
0.541 _ 
, C= [-0.960 -0.541] D = 0.306 
Its equivalent ARX model is: 
y{k) + axy\k -1)+ a2 y(k — 2) = b0u(k) + bxu(k -1) + b2u(k - 2) 
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ax = -1.753, a2 = 0.803,60 =0.306,6, = 0.093, b2 =-0.096 
Figures 5.1 to 5.9 show the results of caffeine model developed for Gum 2 and Gum 
3 population averages. The input impulse level plotted in the figures is scaled down from 
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Figure 5.1: Caffeine model developed for the differential effects between the 
Gum 2 50 mg and placebo cases using population averages. 
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Figure 5.2: Caffeine model developed for the differential effects between the 
Gum 2 100 mg and placebo cases using population averages. 
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Figure 5.3: Caffeine model developed for the differential effects between the 
Gum 2 200 mg and placebo cases using population averages. 
34 
25 n 1 1 1 1 r 
Gum 3 100 mg Low 
—T 1 I I I I i i ~r 
- e — Estimated (RMSE=237) 
— Test 
• Input/10 
• • • • • • • * • • • • • • • * • • • • • • • • • • • • 
J I I I i ' ' I I ' • I I L 
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 
Running Time (min) 
Figure 5.4: Caffeine model developed for the differential effects between the 
Gum 3 100 mg low-user and placebo cases using population averages. 
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Figure 5.5: Caffeine model developed for the differential effects between the 
Gum 3 200 mg low-user and placebo cases using population averages. 
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Figure 5.6: Caffeine model developed for the differential effects between the 
Gum 3 300 mg low-user and placebo cases using population averages. 
25 T 1 1 1 1 r 
Gum 3 100 mg High 
- r T 1 1 r i — i I I r 
-e-Estimated (RMSE=2.57) 
-•—Test 
• Input 10 
• • • • • • • * • • • • • • • * • • • • • • • • • • • • • 
.51 1 1 1 1 1 1 1 1 I _ I 1 1 1 i _ i i_ 
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 
Running Time (min) 
Figure 5.7 Caffeine model developed for the differential effects between the Gum 











Gum 3 200 mg High 
1 1 1 1 1 1 1 1 "" 1 1 1"' 1 1 1 1 1 
—•— Test 
• lmput/10 
Br SI / V \/Ot \ 
7/ W 
^ x 
• • • 
- + + + + + + + • • • • • • • • • • • • • 
1 1 1 1 1 1 1 1 1 1 1 
• • • • * \ | • • • «<k 
i i i i i 
0 30 SO SO 120 150 180 210 240 270 300 330 360 390 420 450 480 
Running Time (min) 
Figure 5.8: Caffeine model developed for the differential effects between the 
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Figure 5.9: Caffeine model developed for the differential effects between the 
Gum 3 300 mg high-user and placebo cases using population averages. 
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5.2 Input Noise Effect 
As shown in Figure 3.7, the caffeine input is structured as impulses proportional to 
the caffeine dose with additive white process noise. However, the additive noise is not 
completely white because of the limited input data points processed. A different noise 
pattern used for model identification would impact the modeling error. Figure 5.11 shows 
that root mean squared error (RMSE) of an identified model can be reduced when more 
input noise patterns are processed. In this study, for each input/output data set, the 
system identification process is repeated for 5,000 different input noise patterns. An 
optimal noise pattern is selected for each data set with a minimum modeling error from 
identified models. Figure 5.10 shows the noise pattern is selected as the best one for Gum 
3 200 mg high-user from 5,000 different input patterns. 
The effect of input noise level on modeling error is also studied. Three different 
noise levels (3%, 5% and 10%), the ratio of the variances of the signals, are investigated 
(see Table 5.1). The result shows that the effect of input noise level on the accuracy of 
the identified model is negligible. In this study, 5% input noise level is used for all 
caffeine model identification cases. 
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Figure 5.10: The best input noise pattern for Gum 3 200 mg high-user. 
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Figure 5.11: Modeling errors (RMSE) as a function of number of additive input 
noise patterns used for running Gum 3 200 mg high-user data. 
5.3 Optimal Caffeine Model Order 
In this section, effect of the model order on the accuracy of an identified model is 
studied. For each case, 5,000 input noise patterns with 5% noise level are used. Table 5.2 
and Figure 5.12 show that as compared to a second-order model, here is no clear 
advantage to using a third-order model for both Gum 2 and Gum 3 population averages. 
Therefore in this study, a second-order caffeine model is used for all test data. 
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Figure 5.12: Modeling errors (RMSE) as a function of estimated system order. 
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5.4 State-space Model in Controllable Canonical Form 
Since the identified state-space model is not unique, several potential model 
structures are considered. As shown in section 5.1, the second-order ARX model can be 
described as 
y(k)+a1y(k -1)+ a2y(k - 2) = b0u(k)+biu(k-\)+ b2u(k - 2) 
Its equivalent discrete transfer function model is 
Y(z) _b0z
2 +blz + b2 
U(z) z2+a1z + a2 
The corresponding state-space model in controllable canonical form is 
x(k +1) = Ax(k) + Bu(k), y(k) = Cx(k) + Du (k) 
0 1 " 
-a2 -a, 
, B = 
"0" 
_1_ 
C = [b2-a2b0 bx-axbQ] = [cx c2], D = bQ=d0 
(5.1) 
This state-space model in controllable canonical form is proposed as the caffeine 
model due to its simplicity and convenience to be merged into a two-process model with 
circadian and homeostatic effects for future study, hi this caffeine model structure, only 
five system parameters [ax,a2,cl,c2,dQ] need to be identified. Table 5.3 shows all the 
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identified model coefficients from the population averages. It is noted that the first two 
coefficients [ax,a2] (see Table 5.4) have small variations for both low and high users of 
caffeine among all doses. This indicates that the caffeine dosage (see Table 5.5 and 
Figure 5.13) and habitual usage (see Table 5.6 and Figure 5.14) do not have much impact 
on caffeine model dynamics controlled by system matrices A and B . 






















































































































































Figure 5.13: Dose effect from population averages 
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Figure 5.14: Habitual effect from population averages 
5.5 Comparison of OKID and ARX Method 
We also use the ARX model (autoregressive with exogenous input model) to identify 
the caffeine model for the Gum 2 and Gum 3 population average data. 
The second-order ARX model can be described as 
y (k) + axy (k -1) + a2y (k-2) = b0u (k) + bxu (k -1) + b2u (k - 2) 
Table 5.7 shows that as compared to a second-order OKID model, there is a clear 
disadvantage of using a second-order ARX model for both Gum 2 and Gum 3 population 
averages. 
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Figure 5.15: Estimation result using an ARX model (2n(* order Least-Squares 
Model for Gum 3 200 mg high-users from population averages). 
Table 5.7: Comparison of OKID and ARX Method 
Data Set 
GUM 2 (AVG) 




































IDENTIFICATION OF INDIVIDUALIZED CAFFEINE MODEL 
The OKID algorithm is also used to identify the caffeine model for Gum 2 and Gum 
3 individual subject data. For Gum 3 data, since the same subject was used repeatedly for 
placebo and other caffeine doses, caffeine-only data can be obtained by subtracting each 
individual subject performance data (100, 200 and 300 mg) from the placebo data (0 mg) 
for the same subject. However, for Gum 2 data, different subjects were used for different 
caffeine doses. So we use the placebo population average as the placebo data for each 
subject to calculate the caffeine-only data for all Gum 2 subjects. 
6.1 Individualized Caffeine Model 
Figures 6.1 to 6.69 show some of the individualized caffeine models developed for 
Gum 2 and Gum 3 subjects. The individualized caffeine model developed usually has a 
larger modeling error as compared to the caffeine model developed from the population 
average data shown in the previous section. 
Table 6.1 to 6.4 and Figure 6.70 show identified model coefficients of individualized 
caffeine models from Gum 2 and Gum 3 data. It is also noted that the first two 
coefficients [aj,a2] have small variations for both low and high users of caffeine among 
all doses. The result shows that the caffeine dosage (see Table 6.5 and Figure 6.71) and 
habitual usage (see Table 6.6 and Figure 6.72) do not have much impact on caffeine 
model dynamics. 
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Figure 6.1: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 504 data and population averages placebo data. 
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0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 
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Figure 6.2: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 506 data and population averages placebo data. 
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Figure 6.3: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 511 data and population averages placebo data. 
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Figure 6.4: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 513 data and population averages placebo data. 
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Figure 6.5: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 517 data and population averages placebo data. 
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Figure 6.6: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 521 data and population averages placebo data. 
51 
Figure 6.7: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 527 data and population averages placebo data. 
Running Time (min) 
Figure 6.8: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 535 data and population averages placebo data. 
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Figure 6.9: Individualized caffeine model developed for the differential effects 
between Gum 2 50 mg subject 539 data and population averages placebo data. 
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Figure 6.10: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 507 data and population averages placebo data. 
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Running Time (min) 
Figure 6.11: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 509 data and population averages placebo data. 
Figure 6.12: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 524 data and population averages placebo data. 
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Figure 6.13: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 526 data and population averages placebo data. 
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Figure 6.14: Individualized caffeine model developed for the differential effects 
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Figure 6.15: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 536 data and population averages placebo data. 
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Figure 6.16: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 537 data and population averages placebo data. 
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Figure 6.17: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 543 data and population averages placebo data. 
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0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 
Running Time (mill) 
Figure 6.18: Individualized caffeine model developed for the differential effects 
between Gum 2 100 mg subject 545 data and population averages placebo data. 
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Figure 6.19: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 508 data and population averages placebo data. 
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Figure 6.20: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 510 data and population averages placebo data. 
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Figure 6.21: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 515 data and population averages placebo data. 
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Figure 6.22: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 522 data and population averages placebo data. 
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Figure 6.23: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 528 data and population averages placebo data. 
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Figure 6.24: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 531 data and population averages placebo data. 
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Figure 6.25: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 533 data and population averages placebo data. 
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Figure 6.26: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 540 data and population averages placebo data. 
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Figure 6.27: Individualized caffeine model developed for the differential effects 
between Gum 2 200 mg subject 541 data and population averages placebo data. 
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Figure 6.28: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 601. 
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Figure 6.29: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 603. 
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Figure 6.30: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 604. 
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Figure 6.31: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 609. 
Running Time (min) 
Figure 6.32: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 610. 
64 








0 ' 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 
Running Time (rain) 
Figure 6.33: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 611. 
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Figure 6.34: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 612. 
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Figure 6.35: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg low-user data and placebo data for subject 616. 
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Figure 6.36: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 601. 
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Figure 6.37: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 603. 
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Figure 6.38: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 604. 
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Figure 6.39: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 609. 
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Figure 6.40: Individualized caffeine model developed for the differential effects 
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Figure 6.41: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 611. 
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Figure 6.42: Individualized caffeine model developed for the differential effects 
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Figure 6.43: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg low-user data and placebo data for subject 616. 
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Figure 6.44: Individualized caffeine model developed for the differential effects 
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Figure 6.45: Individualized caffeine model developed for the differential effects 
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Figure 6.46: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg low-user data and placebo data for subject 604. 
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Subject 609 : Gum 3 300 mg Low 
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Figure 6.47: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg low-user data and placebo data for subject 609. 
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Figure 6.48: Individualized caffeine model developed for the differential effects 
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Figure 6.49: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg low-user data and placebo data for subject 611. 
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Figure 6.50: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg low-user data and placebo data for subject 612. 
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Figure 6.51: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg low-user data and placebo data for subject 616. 
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Figure 6.52: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 602. 
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Figure 6.53: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 605. 
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Figure 6.54: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 608. 
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Figure 6.55: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 613. 
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Figure 6.56: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 614. 
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Figure 6.57: Individualized caffeine model developed for the differential effects 
between Gum 3 100 mg high-user data and placebo data for subject 615. 
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Figure 6.58: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 602. 
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Figure 6.59: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 605. 
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Figure 6.60: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 608. 
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Figure 6.61: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 613. 
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Figure 6.62: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 614. 
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Figure 6.63: Individualized caffeine model developed for the differential effects 
between Gum 3 200 mg high-user data and placebo data for subject 615. 
Running Time (min) 
Figure 6.64: Individualized caffeine model developed for the differential effects 
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Figure 6.65: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg high-user data and placebo data for subject 605. 
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Figure 6.66: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg high-user data and placebo data for subject 608. 
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Figure 6.67: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg high-user data and placebo data for subject 613. 
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Figure 6.68: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg high-user data and placebo data for subject 614. 
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Subject 615 : Gum 3 300 mg High 
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Figure 6.69: Individualized caffeine model developed for the differential effects 
between Gum 3 300 mg high-user data and placebo data for subject 615. 












































































































































































































































































































































































































































































































































































































































a1 a2 d c2 
Dose |mq) 
Figure 6.70: Individualized Caffeine Model Coefficients Statistics 
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Figure 6.71: Individualized Caffeine Model Coefficients Statistics for Dose Effect 
88 









































Lw High Low High Low High Low High Low High 
Figure 72: Individualized Caffeine Model Coefficients Statistics for Habitual Effect 
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6.2 Effect of Caffeine Dosage on Individual Subject Performance 
In this section, we study the effect of caffeine dosage on individual subject 
performance. Since different subjects were used for different caffeine doses in Gum 2 
data, the individual models identified from Gum 2 data are excluded from further analysis. 
Based on the individualized caffeine models identified from Gum 3 data, the 
response of these dose-dependent models to a single 100 mg caffeine input can be 
calculated for each subject (see Figure 6.73). Figure 6.74 shows the statistical response 
among eight low caffeine users from dose-dependent (100, 200 and 300 mg) 
individualized low-user models. Figure 6.75 shows the statistical response among six 
high caffeine users from individualized high-user models. As explained in section 2, a 
higher value of lapses shown in this caffeine-only response data indicates higher alertness. 
The results show that for both low and high caffeine users, the individualized model 
identified from 100 mg test data has statistically higher alertness as compared to the 
response of the identified 200 mg or 300 mg model. 
Caffeine Gum 100 mg 
Caffeine 
Model fop 
^ Subject 1 
V. 
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Figure 6.73: Individualized Performance Prediction Using One Caffeine Dose 
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Figure 6.74: Statistical response of individualized dose-dependent models to a 
single 100 mg caffeine input for eight Gum 3 low-users. 
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Figure 6.75: Statistical response of individualized dose-dependent models to a 
single 100 mg caffeine input for six Gum 3 high-users. 
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6.3 Effect of Habitual Caffeine Usage on Individual Subject 
Performance 
Based on the individualized caffeine models identified from Gum 3 data, the 
response of these models to a single 100 mg dose input can be calculated for each subject. 
Figure 6.76 shows the statistical response of individualized 100 mg models to a single 
100 mg dose input for eight low caffeine users as compared to six high caffeine users. 
The statistical response of individualized 200 mg and 300 mg models is shown in Figure 
6.77 and 6.78, respectively. The results show that both low and high caffeine users have 
comparable responses based on 100 mg models. However, the response of either the 200 
mg or 300 mg model shows that high caffeine users have a statistically higher response 
than low caffeine users. 
Gum 3100 mg 
n—n—r~i—r i i i i T—r 
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Figure 6.76: Statistical response of individualized 100 mg models to a single 
100 mg input for eight low caffeine users as compared to six high caffeine 
users. 
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CHAPTER 7 
CAFFEINE M O D E L PREDICTION 
In this chapter, we study how the identified model for one caffeine dose can be used 
to predict the caffeine effects for other caffeine doses. For a demonstration, the caffeine 
model identified from Gum 3 200 mg high-user population averages is selected to predict 
the caffeine effects of other caffeine doses. The results are shown in Figures 7.1 and 7.2. 
It is clear that the lower 100 mg caffeine dose is much more effective than the 200 mg 
model predicts. A higher 300 mg caffeine dose is less effective than the 200 mg model 
predicts. Moreover, the caffeine model identified from Gum 3 200 mg low-user 
population averages is selected to predict the caffeine effects for Gum 3 100 and 300 mg 
low-user. The results are shown in Figures 7.3 and 7.4. It is clear that the lower 100 mg 
caffeine dose is much more effective than the 200 mg model predicts. A higher caffeine 
dose of 300 mg is less effective than the 200 mg model predicts. In addition, the caffeine 
model identified from Gum 2 100 mg high-user population averages is selected to predict 
the caffeine effects for Gum 2 50 and 200. The results are shown in Figures 7.5 and 7.6. 
It is obvious that the lower 50 mg caffeine dose is much more effective than the 100 mg 
model predicts. A higher 200 mg caffeine dose is less effective than the 100 mg model 
predicts. In section 6.2, it is also found that the individual model identified from the 100 
mg test data set a has statistically higher caffeine response as compared to the response of 
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Figure 7.1: Prediction of 100 mg caffeine effect using 200 mg model for high-
users based on population average data. 
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Figure 7.2: Prediction of 300 mg caffeine effect using 200 mg model for high-
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Figure 7.3: Prediction of 100 mg caffeine effect using 200 mg model for low-
users based on population average data. 
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Figure 7.4: Prediction of 300 mg caffeine effect using 200 mg model for low-
users based on population average data. 
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Figure 7.5: Prediction of 50 mg caffeine effect using 100 mg model for Gum 2 
based on population average data. 
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Figure 7.6: Prediction of 200 mg caffeine effect using 100 mg model for Gum 
2 based on population average data. 
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To improve model prediction, a dose factor K is introduced as the scale factor for the 
input dose level. As shown in Figure 7.7, the state-space caffeine model used for 
prediction is modified as: 
x(k + l) = Ax(k) + BKu(k) 
y(Jc) = Cx(k) + I)Ku(k) ' 
The optimal dose factor K for Gum 3 high-user 100 mg and 300 mg can be obtained 
by minimizing the root mean squared error for the prediction. The improved prediction 
using the 200 mg high-user model with the optimal dose factor for the 100 and 300 mg 
dose is shown in Figures 7.8 and 7.9, respectively. 
The optimal dose factor K for Gum 3 low-user 100 mg and 300 mg can be obtained 
by minimizing the root mean squared error for the prediction. The improved prediction 
using 200 mg low-user model with the optimal dose factor for 100 and 300 mg doses is 
shown in Figures 7.10 and 7.11, respectively. 
The optimal dose factor K for Gum 2 50 mg and 200 mg can be obtained by 
minimizing the root mean squared error for the prediction. The improved prediction 
using 100 mg model with the optimal dose factor for the 50 and 200 mg doses is shown 
in Figures 7.12 and 7.13, respectively. 
The use of dose factor to improve model prediction is also applied to all population 
averages and individualized models in Figure 7.14 and 7.15. Figure 7.15 shows that the 
dose factor is higher at low caffeine dose (100 mg) and lower at high caffeine dose (300 
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Figure 7.7: Use of dose factor K to adjust input caffeine level for model prediction. 
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Figure 7.8: Prediction of 100 mg caffeine effect using 200 mg model and an 
optimal dose factor for high-users based on population average data. 
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Figure 7.9: Prediction of 300 mg caffeine effect using 200 mg model and an 
optimal dose factor for high-users based on population average data. 
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Figure 7.10: Prediction of 100 mg caffeine effect using 200 mg model and an 
optimal dose factor for low-users based on population average data. 
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Figure 7.11: Prediction of 300 mg caffeine effect using 200 mg model and an 
optimal dose factor for low-users based on population average data. 
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Figure 7.12: Prediction of 50 mg caffeine effect using 100 mg model and an 
optimal dose factor for Gum 2 on population average data. 
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Figure 7.13: Prediction of 200 mg caffeine effect using 100 mg model and an 
optimal dose factor for Gum 2 on population average data. 
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Figure 7.14: Optimal dose factor K vs. caffeine level for Gum 2 and Gum 3 based 
on population average data. 
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In this study, the following caffeine model is proposed: 
x(k +1) = Ax{k) + Bu(k), y(k) = Cx(k) + Du(k) 
(8.1) 
, C= [cx c2\ D = d0 
This second-order state-space model in controllable canonical form can be easily 
merged into a two-process model with circadian and homeostatic effects for future study. 
In this caffeine model, five system parameters [ax,a2,cx,c2,d0'\ can be identified by 
using the proposed Observer/Kalman filter identification (OKID) algorithm. 
Identification of individualized caffeine model shows that the first two coefficients 
\ax ,a2 ] have small variations for both low and high caffeine users among all doses. This 
indicates that the caffeine dosage and habitual usage do not have much impact on the 
individualized caffeine model dynamics. 
Based on the individualized caffeine models identified from Gum 3 data, the 100 mg 
model has a statistically higher caffeine response as compared to the response of the 200 
mg or 300 mg models. The result also shows that both low and high caffeine users have 
A = 
0 1 
• a - , 
B = 
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comparable responses based on the 100 mg model. However, the responses of the 200 
mg or 300 mg models show that high caffeine users have statistically higher responses to 
caffeine. 
Finally, it is shown that the proposed individualized caffeine model can be modified 
by adding a dose factor to the input of the model to improve the prediction for the 
performance of other caffeine doses. 
8.2 Areas for Future Work 
The research will be extended in one-step ahead prediction by using the same test 
data as studied for prospective study since the identified caffeine models can be used for 
prediction of future performance. The second-order state-space model in controllable 
canonical form can be easily merged into a two-process model with circadian and 
homeostatic effects. Therefore, the future work will be integrated into the dynamic two-
process model of human performance, and then adapt the estimation and forecasting 
algorithm for the new, larger model. The first step will be to transform the caffeine model 
so that its structure is described in the form of a nonlinear state space model, as required 
by the Bayesian forecasting algorithm. Furthermore, future work will also integrate the 
caffeine parameters into the existing two-process model to create a single integrated 
model. At this point, the work will be given a fatigue and performance model that has a 
sleep/wake input, a chronic sleep restriction parameter and a caffeine input with 
associated caffeine parameters. Eventually, the estimation algorithm will be reconfigured 
for use with the expanded model, by introducing a new caffeine input to specify timing 
106 
and quantity of doses, redesigning the algorithm for the expanded number of states and 
inputs, and then selecting new tuning parameters for process covariances. 
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APPENDIX A 
SINGLE TRIAL CAFFEINE DOSES 
Definition Al (Gum 2) Laboratory-based conducted by the Division of Neuropsychiatry, 
Walter Reed Army Institute of Research, involving a range of multiple caffeine doses 
(three repeated doses of Omg, 50mg, lOOmg, or 200mg) during one night total sleep 
deprivation. 
Description of protocol: 
(a) 1 baseline day of 8 hours TIB (23:00 to 7:00). 
(b) 1 night of total sleep deprivation with three repeated caffeine dosages administered at 
2 hour intervals to four experimental groups. 
Definition A2 (Gum 2 Omg) Placebo administered at 03:00, 05:00 and 07:00. 
Definition A3 (Gum 2 50mg) 50mg dosage administered at 03:00, 05:00 and 07:00. 
Definition A4 (Gum 2 lOOmg) lOOmg dosage administered at 03:00, 05:00 and 07:00. 
Definition A5 (Gum 2 200mg) 200mg dosage administered at 03:00, 05:00 and 07:00. 
113 
APPENDIX B 
REPEATED TRIAL CAFFEINE DOSES 
Definition Bl (Gum 3) Laboratory-based conducted by the Division of Neuropsychiatry, 
Walter Reed Army Institute of Research, involving a range of multiple caffeine doses 
(three repeated doses of Omg, 50mg, lOOmg, or 200mg) during one night total sleep 
deprivation. Two groups participated, low users of caffeine and high users. Each subject 
will complete four separate trials with a minimum of four weeks between trials. 
Description of protocol: 
(a) 1 baseline day of 8 hours TIB (23:00 to 7:00). 
(b) 1 night of total sleep with repeated caffeine dosages to low users of caffeine and high 
users. Participants completed four separate trials with a minimum of four weeks between 
trials. At each trial subjects were given three repeated doses of caffeine (Omg, lOOmg, 
200mg, or 300mg) at two hour intervals. 
Definition B2 (Gum 3 Low Omg) Placebo administered at 03:00, 05:00 and 07:00. 
Definition B3 (Gum 3 Low lOOmg) lOOmg dosage administered at 03:00, 05:00 and 
07:00. 
Definition B4 (Gum 3 Low 200mg) 200mg dosage administered at 03:00, 05:00 and 
07:00. 
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Definition B5 (Gum 3 Low 300mg) 300mg dosage administered at 03:00, 05:00 and 
07:00. 
Definition B6 (Gum 3 High Omg) Placebo administered at 03:00, 05:00 and 07:00. 
Definition B7 (Gum 3 High lOOmg) lOOmg dosage administered at 03:00, 05:00 and 
07:00. 
Definition B8 (Gum 3 High 200mg) 200mg dosage administered at 03:00, 05:00 and 
07:00. 
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